Wednesday, June 27, 2012

Friday, June 22, 2012

Alzheimer's: Bapineuzumab and Solanezumab

Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs
Ransdell Pierson | Reuters
The Chicago Tribune
June 19, 2012


"Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for the investment research services group. Wall Street is eagerly awaiting results of the trials and expects huge potential sales if either of the medicines proves able to arrest the progression of the memory-robbing disease.

"Pfizer and Lilly are expected in the third quarter to disclose the main findings from large studies of their respective medicines, bapineuzumab and solanezumab. Complete data are expected to be presented at medical meetings in the fourth quarter.

"The survey responders, on average, gave solanezumab only a 14 percent chance of meeting all the primary goals of its two Phase III studies, compared with an average 21 percent probability for the two big trials of bapineuzumab, Schoenebaum said."


Read the full article

Comments by the Pharmalot blog on this report, from the 20th of June:

Read the blog entry from Pharmalot.

Neuropsychology Abstract of the Day: Diagnostic Value of Subjective Complaints

Understanding the relation between subjective complaints and objective performance findings is always a crucial factor in clinical assessment. It is a source of debate by clinicians and researchers and a literature has developed examining the issues that are generated by the relation. Here, an example:

Lenehan ME, Klekociuk SZ, Summers MJ. Absence of a relationship between subjective memory complaint and objective memory impairment in mild cognitive impairment (MCI): is it time to abandon subjective memory complaint as an MCI diagnostic criterion? Int Psychogeriatr. 2012 May 1: 1-10. [Epub ahead of print]


Background: Subjective memory complaints are a requirement in the diagnosis of mild cognitive impairment (MCI) as they are thought to indicate a decline in objective memory performance. However, recent research suggests that the relationship between subjective memory complaint and objective memory impairment is less clear. Thus, it is possible that many people without subjective memory complaints who develop Alzheimer's disease are precluded from a diagnosis of MCI.Methods: The present study examined the relationship between subjective memory complaint assessed using the Multifactorial Memory Questionnaire (MMQ) and objective memory impairment assessed using standard neuropsychological measures in cases of amnestic MCI (n = 48), non-amnestic MCI (n = 27), and unimpaired healthy participants (n = 64).Results: Correlational and regression analyses indicated that subjective memory complaints displayed a poor relationship with objective memory performance. A subsequent discriminant function analysis indicated that subjective memory complaints failed to improve the diagnostic accuracy of MCI and resulted in increased rates of false negative and false positive diagnoses.Conclusion: The results of the present study suggest that a diagnostic criterion of subjective memory complaint reduces the accuracy of MCI diagnosis, resulting in an elevated rate of false positive and false negative diagnoses. The results of this study in conjunction with recent research indicate that a criterion of subjective memory complaint should be discarded from emerging diagnostic criteria for MCI.

PMID: 22717042 [PubMed - as supplied by publisher]

Wednesday, June 20, 2012

Neuropsychology Abstract of the Day: TrkB

Boulle F, Kenis G, Cazorla M, Hamon M, Steinbusch HH, Lanfumey L, A van den Hove DL. TrkB inhibition as a therapeutic target for CNS-related disorders. Prog Neurobiol. 2012 Jun 12. [Epub ahead of print]


The interaction of brain-derived neurotrophic factor (BDNF) with its tropomyosin-related kinase receptor B (TrkB) is involved in fundamental cellular processes including neuronal proliferation, differentiation and survival as well as neurotransmitter release and synaptic plasticity. TrkB signaling has been widely associated with beneficial, trophic effects and many commonly used psychotropic drugs aim to increase BDNF levels in the brain. However, it is likely that a prolonged increased TrkB activation is observed in many pathological conditions, which may underlie the development and course of clinical symptoms. Interestingly, genetic and pharmacological studies aiming at decreasing TrkB activation in rodent models mimicking human pathology have demonstrated a promising therapeutic landscape for TrkB inhibitors in the treatment of various diseases, e.g. central nervous system (CNS) disorders and several types of cancer. Up to date, only a few selective and potent TrkB inhibitors have been developed. As such, the use of crystallography and in silico approaches to model BDNF-TrkB interaction and to generate relevant pharmacophores represents powerful tools to develop novel compounds targeting the TrkB receptor.
Copyright © 2012. Published by Elsevier Ltd.

PMID: 22705453 [PubMed - as supplied by publisher]

Saturday, June 09, 2012

Alzheimer's Disease: "How Do You Live Knowing You Might Have an Alzheimer’s Gene?"

How Do You Live Knowing You Might Have an Alzheimer’s Gene?
The New York Times
07 June 2012

Read the full article

Alzheimer's Disease: CAD106 Phase I Results

Vaccine which could help delay Alzheimer's by five years passes first test
Daily Record (UK)
By Mike Swain
09 June 2012

Read the full article

Abstract of publication in Lancet Neurology: link here